Search

Copyright of Osmangazi Journal of Medicine / Osmangazi Tip Dergisi is the property of Eskisehir Osmangazi University and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

This article, published in the International Journal of Rheumatic Diseases, explores the impact of antineutrophil cytoplasmic antibody (ANCA) subtype and diagnostic subgroups of ANCA-associated vasculitis (AAV) on pulmonary involvement patterns detected on thoracic high-resolution CT in patients with AAV. The study included 64 patients with AAV and found that the most common abnormal findings on CT were consolidation, nodules, cavities, and ground-glass opacity. The study also compared the findings between different ANCA subtypes and diagnostic subgroups, finding that certain CT findings were more common in specific subgroups. Overall, the study suggests that classification according to ANCA subtype does not provide additional information regarding pulmonary findings on thoracic CT in patients with AAV. [Extracted from the article]

Background: This study aimed to examine fetomaternal outcomes in pregnant women in a large Turkish Takayasu arteritis (TAK) cohort and to evaluate the effects of pregnancy on the disease in those patients. Methods: This is a cohort study involving 296 pregnancies of 112 TAK patients from 8 tertiary rheumatology centers in Turkey. Pregnancies were divided into 2 groups as pre‐d (before disease onset) and post‐d (after disease onset). In addition, post‐d pregnancies were further divided into 2 subgroups according to fetomaternal complications (FMC) development status. Finally, patients were grouped into those with and without a history of pregnancy after disease onset. Results: In post‐d pregnancies, rates of worsening hypertension, new‐onset hypertension, and preeclampsia were higher than in pre‐d pregnancies (0.9% vs 16%, P <.001, 0.5% vs 5.3%, P =.012, and 0% vs 4%, P =.013, respectively). Patients with FMC were more likely to have renal artery involvement (65% vs 21%, P =.003). The patients who had post‐d were younger, had longer disease duration, and had more relapses number than other patients (P <.001, P =.028, P =.016, respectively). Vasculitis Damage Index (VDI) results were similar in patients with or without post‐d pregnancies. Conclusion: Pregnancies after disease onset were found to be associated with HT and preeclampsia/eclampsia. HT‐related FMCs are increased in TAK, and patients with renal artery involvement are at higher risk. The number of relapses increases in patients who become pregnant after disease onset, but pregnancy was not an independent risk factor for relapse. Pregnancy after the onset of disease had no negative effect on VDI. [ABSTRACT FROM AUTHOR]

Objective: Sjögren syndrome is a systemic inflammatory disease causing gland dysfunction. Few (and contradictory) reports on the mucosal effects of Sjögren syndrome have appeared. Here, we objectively demonstrate nasal dryness in Sjögren syndrome patients and explore the effect of such dryness on olfaction. Methods: Thirty‐four consecutive patients with primary Sjögren syndrome were enrolled in this cross‐sectional study. The control group consisted of 21 age‐ and sex‐matched volunteers. Medical histories and nasal findings were recorded. The Connecticut Chemosensory Clinical Research Center test was used to evaluate olfactory function. All subjects underwent mucucociliary clearance analysis (the saccharin test and peak nasal inspiratory flowmetry). The intranasal Schirmer test was used to evaluate the nasal cavity. Results: The nasal Schirmer test scores were 8.4 mm (right) and 8 mm (left) (P =.041, P =.016, respectively, compared to controls). The Chi‐squared test revealed significant differences (compared to controls) in nasal dryness (P =.001), postnasal drip (P =.04), and smell (a decrease) (P =.005). Neither olfactory function nor mucociliary clearance differed between the groups. We noted a trend toward a positive correlation between olfactory function and the nasal Schirmer score but statistical significance was not attained. Conclusion: The intranasal Schirmer test objectively showed that Sjögren syndrome patients exhibited nasal cavity dryness; this is useful in terms of follow‐up. This did not affect olfactory function. Level of Evidence: 4 Laryngoscope, 131:370–373, 2021 [ABSTRACT FROM AUTHOR]

Copyright of Journal of Turkish Society for Rheumatology is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Turkish Society for Rheumatology is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Turkish Society for Rheumatology is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Turkish Society for Rheumatology is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Turkish Society for Rheumatology is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Turkish Society for Rheumatology is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Amaç: Önceleri pre-B hücre koloni geliştirme faktörü olarak bilinenvisfatin, adipositler, malcrofajlar ve nötrofillerce üretilir. Romatoidartrit (RA) hastalarında dolaşımdaki visfatin seviyele-riıün anlamlı seviyede yükseldiği ve hastalık aktivitesi ile pozitif korelasyon gösterdiği ileri sürülmüştür. Nesfatin ilk olarak hi-potalamustan salgılanan anoreksijenik bir molekül olarak tanımlanmıştır, bununla birlikte adipositler, gastrik mukoza ve pankreastan da salgılanır. Yakm zamandaki çalışmalar nesfati-nin anti-inflamatuvar bir molekül olduğunu ve kardiyovasküler riski azalttığım göstermiştir. Buna rağmen, RA hastalarında serum nesfatin seviyeleri daha önce değerlendirilmemiştir. Bu nedenle, bu çakşmanm amacı RA hastalarında serum nesfatin seviyelerim değerlendirmek ve sağhklı kontroller ile karşılaştırmaktır. Yöntem: 2010 ACR/EULAR kriterlerine göre taıu almış toplam 69 RA hastası [58 kadın (%84); ortalama yaş: 49.8±10.2] ve 50sağhklı kontrol [40 kadın (%80); ortalama yaş: 46.5±8.7] çalışmaya dahil edildi. Serum nesfatin ve visfatin seviyeleri ELI-SA kitleri ile belirlendi. Hastalığa ilişkili bilgiler yanında karo-tidintima-media kalınlığı ve HOMA skorları gibi verilerde toplandı. Bulgular: Beklendiği üzere serum CRP seviyeleri RA hastalarında kontrollere göre daha yüksek bulundu (sırasıyla 1.1 ±1.7 ve 0.3±0.2 mg/dL; p<0.001). Romatoid faktör (RF) 43 hastada (%62), anti-siklik sitrülinepeptid antikor (anti-CCP) 49 hastada (%71) pozitifti. Kontrollere göre RA hastalarında visfatin seviyeleri yüksek olma eğiliminde olmasına rağmen hu fark anlamlı bir seviyeye ulaşmadı (sırasıyla 2.7±2.8 ve 2.5± 1.4 ng/mL; p=0.288). Çahşma grubumuzda serum nesfatin seviyeleri RA hastalarında anlamlı derecede yüksekti (sırasıyla 95.9± 170.2 ve 35.0±60.1 pg/mL; p<0.001). Serum nesfatin seviyelerüle RF (r=0.327; p=0.002) ve anti-CCP (r=0.282; p=0.007) pozitifliği arasında ilişki idi. Bununla birlikte, serum nesfatin veya visfatin seviyeleri ile yaş, ciasiyet, hastalık aktivitesi belirteçleri (CRP, ESR, DAS-28), karotid intima-nıedia kalınlığı ve HOMA skorları arasmda korelasyon bulunmadı. Bulgular: Bu çalışmanın sonuçları RA hastalarında serum nesfatin seviyelerinin anlamlı şekilde daha yüksek olduğunu göstermektedir. Nesfatin RA için bir yatkınlık ve/veya şiddet ilişkili faktör olabilir. Ancak hastalık aktivitesi ile ilişkili görülmemektedir. [ABSTRACT FROM AUTHOR]

Objective: To evaluate the development of anti-drug antibodies (ADAb) against tumor necrosis factor inhibitors (TNFi) therapy during a 2-year period and search the factors linked to patients with axial spondyloarthritis (axSpA)., Methods: Biologic-naive patients with axSpA were included in this observational study. Serum drug levels and ADAb were measured at weeks 12, 24, 52, and 104 of treatment by enzyme-linked immunosorbent assay (ELISA). The development of ADAb and factors related to ADAb over time were investigated using generalized estimating equations (GEE)., Results: A total of 180 patients with axSpA (116 male, mean (±SD) 45.6 (±11.9) years) who started TNFi treatment (etanercept (32.2%), adalimumab (27.2%), golimumab (20.6%), infliximab (20%)) were included. In the etanercept treatment group, only 1 patient had ADAb at 12 weeks and 24 weeks. Anti-drug antibodies against TNFi drugs were present in the adalimumab group in 32.7% of patients and in the infliximab group in 21.2% of patients at 12 weeks, and the proportion of ADAb-positive patients were found to be stable throughout the follow-up for adalimumab- and infliximab-treated patients. In the golimumab group, one patient had ADAb against golimumab at 12 weeks and the proportion of ADAb-positive patients increased throughout follow-up. In longitudinal analysis, baseline age, TNFi type, longitudinal Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and ASDAS-CRP scores, serum C-eeactive protein (CRP) levels, presence of adverse events and treatment discontinuation were associated with the presence of ADAb., Conclusion: The development of ADAb against TNFi therapy is associated with younger age, high disease activity, the development of adverse events and more common treatment discontinuation in patients with axSpA during 2-year follow-up.

Background/aim: The TReasure registry, created in 2017, is an observational multicenter cohort that includes inflammatory arthritis patients. This article reviews the methodology and objectives of the TReasure registry established to collect data from rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients., Methodology: Fifteen rheumatology centers in Turkey will contribute data to the TReasure database. The actual proprietor of the database is the Hacettepe Rheumatology Association (HRD) and Hacettepe Financial Enterprises. Pharmaceutical companies that operate in Turkey (in alphabetical or er), Abbvie, Amgen, BMS, Celltrion Healthcare, Novartis, Pfizer, Roche, and UCB, support the TReasure registry. TReasure is a web-based database to which users connect through a URL (https://www.trials-network.org/treasure) with their unique identifier and passwords provided for data entry and access. TReasure records demographic and clinical features, comorbidities, radiology and laboratory results, measures of disease activity, and treatment data., Discussion: TReasure will provide us with various types of data, such as a cross-sectional view of the current nationwide status of the patients currently receiving these treatments, and retrospective data as much as allowed by the participating centers’ records. Finally, a high-quality prospective dataset will be built over the ensuing years from patients with a new diagnosis of RA or SpA.